MTOR and mantle cell lymphoma: The demonstrated activity of bortezomib in MCL, and the mTOR inhibitors everolimus and temsirolimus in DLBCL and MCL, suggests that these agents may one day have a place in the treatment armamentarium for aggressive lymphomas.